BioRestorative Therapies (BRTX) Share-based Compensation (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Share-based Compensation came in at $447860.0 in Q4 2025, up 155.01% YoY from $175625.0 in Q4 2024, and up 11.98% on a QoQ basis from $399932.0 in Q3 2025.
BioRestorative Therapies (BRTX) Share-based Compensation (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Share-based Compensation data on file, last reported at $447860.0 in Q4 2025.
- Quarterly Share-based Compensation rose 155.01% year-over-year to $447860.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (up 18.24% YoY) and the FY2025 annual result came in at $3.3 million, up 18.24% from the prior year.
- Share-based Compensation improved to $447860.0 in Q4 2025, from $399932.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $13.9 million in Q1 2021 to a low of -$6.3 million in Q4 2023.
- A 5-year average of $1.5 million and a median of $977188.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation surged 6163.57% — and 2023, when it slumped 306.36%.
- Tracing BRTX's Share-based Compensation over 5 years: stood at -$291900.0 in 2021, then surged by 1147.71% to $3.1 million in 2022, then tumbled by 306.36% to -$6.3 million in 2023, then jumped by 102.78% to $175625.0 in 2024, then soared by 155.01% to $447860.0 in 2025.
- The last three Share-based Compensation figures came in at $447860.0 (Q4 2025), $399932.0 (Q3 2025), and $468708.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | - |
| 10 | BioRestorative Therapies | 1.93 Mn | -1.02 Mn | 17,964.00 | 447,860.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 447,860.00 |
| Dec 31, 2025 | 447,860.00 |
| Sep 30, 2025 | 399,932.00 |
| Sep 30, 2025 | 399,932.00 |
| Jun 30, 2025 | 468,708.00 |
| Jun 30, 2025 | 468,708.00 |
| Mar 31, 2025 | 2.01 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Dec 31, 2024 | 175,625.00 |
| Dec 31, 2024 | 175,625.00 |
| Sep 30, 2024 | 284,245.00 |
| Sep 30, 2024 | 284,245.00 |
| Jun 30, 2024 | 324,322.00 |
| Jun 30, 2024 | 324,322.00 |
| Mar 31, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | -6.31 Mn |
| Dec 31, 2023 | -6.31 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Sep 30, 2023 | 1.49 Mn |